22:58 , Apr 4, 2019 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: March 2019

New Therapeutic Targets and Biomarkers: March 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during March. Therapeutic targets are defined as any protein, gene or other molecule...
21:16 , Mar 5, 2019 |  BC Innovations  |  Distillery Therapeutics

MC1R, ZDHHC13 and LYPLA2 as new targets for melanoma

DISEASE CATEGORY: Cancer INDICATION: Melanoma Mouse studies suggest activating MC1R by expressing ZDHHC13 or inhibiting LYPLA2 could help treat melanoma. In a mouse model of melanoma, transgenic expression of human ZDHHC13, which palmitoylates MC1R to...
21:18 , Feb 11, 2019 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Melanoma In vitro , cell culture and mouse studies identified a quinazolinamine-based STK19 inhibitor that could help treat NRAS-mutant melanoma. In vitro screening of a small molecule library and optimization of the top hit...
19:52 , Jun 28, 2018 |  BC Innovations  |  Emerging Company Profile

Stress relief for neurons

Aquinnah Pharmaceuticals is developing disease-modifying therapies for amyotrophic lateral sclerosis and Alzheimer’s disease by inhibiting the formation of stress granules that promote protein aggregation in neurons. Stress granules are protein-RNA complexes assembled by RNA-binding proteins...
20:26 , Feb 2, 2018 |  BC Week In Review  |  Company News

Eisai, Boston University School of Medicine partner to study microglia in AD

Eisai Co. Ltd. (Tokyo:4523) and the Boston University School of Medicine partnered to study the effects of Alzheimer’s disease-associated genetic variants on the behavior of microglia. Under the two-year deal, Eisai’s immuno-dementia discovery R&D team...
19:00 , Jan 4, 2018 |  BC Innovations  |  Translation in Brief

New Therapeutic Targets and Biomarkers: December 2017

New Therapeutic Targets and Biomarkers: December 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during December 2017. Therapeutic targets are defined as any protein, gene or other...
20:49 , Dec 14, 2017 |  BC Innovations  |  Translation in Brief

STUBbing out thrombosis

Patients with chronic kidney disease are at a higher risk of thrombosis, especially following surgery and dialysis, but are also at a higher risk of bleeding than healthy individuals, making standard antithrombotic therapies dangerous. A...
01:09 , Dec 13, 2017 |  BC Innovations  |  Distillery Therapeutics

Endocrine / Metabolic

INDICATION: Pompe's disease Mouse studies suggest gene therapies delivering secretion-optimized GAA variants could help treat Pompe’s disease. The gene therapies consist of a liver-tropic adeno-associated viral serotype 8 (AAV8) vector encoding one of two GAA...
19:32 , Dec 5, 2017 |  BC Innovations  |  Distillery Techniques

Chemistry

TECHNOLOGY: Tool compounds A GNAI3-based inhibitor could help probe the role of GBA motif-containing proteins in cancer. The inhibitor, which competitively inhibits binding between wild-type GNAI3 and GBA motif proteins, is a GNAI3 variant containing...
21:48 , Apr 20, 2017 |  BC Innovations  |  Finance

Zuckerberg’s research network

The Chan Zuckerberg Biohub took its first concrete steps toward knitting together the Bay Area research base with the announcement of the first class of its $50 million CZ Biohub Investigators program. The idea is...